Cardiovascular disease in patients with spondyloarthropathies

Joint Bone Spine. 2008 Jan;75(1):18-21. doi: 10.1016/j.jbspin.2007.04.011. Epub 2007 Aug 14.

Abstract

Spondyloarthropathies are associated with a greater cardiovascular risk than expected based on the cardiac lesions known to occur in these diseases. The prevalence of several conventional risk factors is high in spondyloarthropathy patients, and chronic inflammation also contributes to premature plaque formation. In addition, susceptibility genes for spondyloarthropathies may be associated with an increased risk of cardiovascular disease. Finally, several drugs used to treat spondyloarthropathies may contribute to the occurrence of cardiovascular events. A careful evaluation of the cardiovascular risk profile is a key component of the management of patients with spondyloarthropathies.

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use
  • Atherosclerosis / physiopathology
  • Atrioventricular Block / epidemiology
  • Atrioventricular Block / genetics
  • Cardiovascular Diseases / epidemiology*
  • Comorbidity
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Genetic Predisposition to Disease
  • HLA-B27 Antigen / genetics
  • Heart Conduction System / physiopathology
  • Heart Valve Diseases / epidemiology
  • Humans
  • Lactones / pharmacology
  • Lactones / therapeutic use
  • Risk Factors
  • Smoking / epidemiology
  • Spondylarthropathies / drug therapy
  • Spondylarthropathies / epidemiology*
  • Spondylarthropathies / genetics
  • Sulfones / pharmacology
  • Sulfones / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antirheumatic Agents
  • Cyclooxygenase 2 Inhibitors
  • HLA-B27 Antigen
  • Lactones
  • Sulfones
  • Tumor Necrosis Factor-alpha
  • rofecoxib